Informationen und Ansprechpartner zu METIS / EF-25
| Studienbeschreibung |
| EF-25 | METIS / EF-25 |
| Studientitel | Pivotal, open-label, randomized study of radiosurgery with
or without Tumor Treating Fields (TTFields) for 1-10 brain
metastases from non-small cell lung cancer (NSCLC). |
| Kurzbeschreibung | The METIS trial (also known as the EF-25 trial) is a pivotal (analogous to drug Phase III), randomized, controlled trial, designed to test the efficacy and safety of Tumor Treating Fields (TTFields), generated by a medical device, the NovoTTF-100M System in patients with 1-10 newly diagnosed brain metastases from non-small cell lung cancer (NSCLC. TTFields are administered to patients concomitantly with the best standard of care treatments which would normally be used to treat lung cancer. The trial is expected
to enroll a total of 270 patients. |
| Betreffendes Organsystem | Hirntumoren
(Hirntumoren, Hypophysentumoren) |
| Gesamte Studienbeschreibung | https://clinicaltrials.gov/ct2/show/NCT02831959 |
| Studientyp | Therapie-Studie |
| Studienstatus | Rekrutierung offen (Teilnehmer werden aufgenommen) |
Für weitere Informationen - auch zu den Ein-/Auschlusskriterien - wenden Sie sich bitte an die oben genannten Ansprechpartner im Studienzentrum.
